0
Editor's Correspondence |

Treatment of MRSA Infections With Older Molecules: A Reasonable Option for Investigation—Reply

Annie Wong-Beringer, PharmD; Levita K. Hidayat, PharmD; Donald I. Hsu, PharmD
Arch Intern Med. 2007;167(11):1208-1209. doi:10.1001/archinte.167.11.1208.
Text Size: A A A
Published online

Extract

In reply

We are pleased to capture the attention of our colleagues and appreciate the opportunity to provide further discussions related to our prospective observational study examining the efficacy and safety of high-dose vancomycin therapy for the treatment of MRSA.1 Johnson requested definitions of “target” and “corrected” troughs used and an explanation of the outcome analysis performed in our study. Target trough was defined as achievement of an unbound vancomycin concentration at 4 to 5 times the MIC of the infected strain.1(p2139) Thus, for a strain with an MIC of 2 μg/mL and taking into account the 50% protein-binding property of vancomycin, attaining a target trough of 16 to 20 μg/mL is necessary to achieve 4 to 5 times the MIC of the infected strain, respectively (eg, bound + unbound drug concentration of 16 μg/mL = 2 μg/mL × 2 × 4). To determine the overall drug exposure during the course of therapy, we calculated a “corrected” trough for each patient, defined as the sum of each measured trough concentration multiplied by the number of days at that level, then divided by the number of total days of treatment.1(p2139) The “corrected” trough value was used to subgroup patients based on the achievement of the target trough in the efficacy analysis and the attainment of high vs low trough level in the safety analysis. Faulhaber et al raised concerns regarding the calculation of arithmetic rather than geometric mean of the trough levels attained. Both geometric and arithmetic means of the corrected vancomycin trough were calculated to be similar and did not result in different distribution of patient subgroups. Treatment response was evaluated at 2 time points, at 72 hours following initiation of therapy and end of treatment—“corrected” trough values based on the days of drug exposure were used accordingly, with the results shown in Figures 1 and 2, respectively.1(p2140) We observed a 20% lower response rate for those who did not achieve the target trough initially (52/68 [76%] vs 15/27 [56%]; P = .05); thus, aggressive empirical vancomycin dosing to achieve a trough greater than 15 μg/mL is recommended until the culture and sensitivity results are known.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();